98%
921
2 minutes
20
Introduction: The role of anticoagulation in octogenarians and nonagenarians with atrial fibrillation (AF) is controversial due to the lack of evidence from randomized controlled trials (RCTs), owing to the under representation of these patients in clinical trials.
Aim: In the present meta-analysis we aim at comparing the clinical benefits and risk of anticoagulation (AC) with no AC in octogenarians and nonagenarians.
Methods: We systematically searched MEDLINE/PubMed, EMBASE/Ovid, and Web of Science databases from the inception to October, 2020. Studies were eligible for inclusion if they met the following criteria: studies comparing AC with no AC in patients aged 80 or more for AF and reported thromboembolic events (TE) and bleeding outcomes. We used Mantel-Haenszel method with a Paule-Mandel estimator of Tau with Hartung Knapp-Sidik-Jonkman adjustment to estimate risk ratio (RR) with a 95% confidence interval (CI). Outlier analysis was used to adjust for statistical heterogeneity.
Results: A total of 10 observation studies and 1 RCT were included in the final analysis. There was no difference in the risk of TE with AC in octogenarians and nonagenarians compared with no AC, before [RR: 0.87, 95% CI 0.62-1.23, I: 71%, GRADE confidence "very low"] and after [RR: 0.83, 95% CI 0.66-1.04, I: 55.5%] adjusting for statistical heterogeneity among studies. In the unadjusted analysis, no difference in the risk of bleeding events was observed between both groups [RR: 1.05, 95% CI 0.62-1.77, I: 86%, GRADE confidence "very low"]. After adjusting for heterogeneity, AC was associated with an increased risk of bleeding compared with those not receiving AC [RR: 1.57, 95% CI 1.44-1.71, I: 0%]. AC in octogenarians was not associated with a net clinical benefit compared with no AC.
Conclusions: This meta-analysis did not demonstrate any difference in the risk TE in octogenarians and nonagenarians with AF on AC vs. no AC, in both the adjusted and unadjusted analyses. Also, the risk of bleeding events in the unadjusted analysis was similar between both groups. The adjusted analysis showed an increased risk of bleeding in the AC group compared with no AC group. More data is needed to establish safety and efficacy of AC in this vulnerable patient population. The results of this analysis should be interpreted with caution due to the observational nature of most studies included, and the only RCT reported lower rates of TE and similar risk of bleeding.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s40292-021-00442-0 | DOI Listing |
Clin Pharmacol Ther
September 2025
Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation but are associated with gastrointestinal (GI) bleeding. While this risk is well established, most studies evaluate NSAIDs as a homogenous class, limiting clinical decision-making based on individual agent safety. This systematic review and meta-analysis aimed to quantify the risk of GI bleeding associated with individual NSAIDs.
View Article and Find Full Text PDFJ Thromb Haemost
September 2025
Department of Medicine and Ageing Sciences, Gabriele D'Annunzio University, Chieti, Italy.
Background: Recurrent venous thromboembolism (VTE) is a common complication in patients with cancer-associated VTE. Limited data are available on treatment, particularly in patients receiving direct oral anticoagulants (DOACs). We aimed to evaluate current management strategies and outcomes in patients with cancer and recurrent VTE during treatment with low-molecular-weight heparin (LMWH) or DOACs.
View Article and Find Full Text PDFContraception
September 2025
Division of Reproductive Health, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, Atlanta, GA, United States, 30341.
Objectives: To systematically review evidence on the safety and effectiveness of contraceptive use among women with chronic kidney disease (CKD).
Study Design: We searched for articles in multiple databases from database inception through December 12, 2022, that assessed safety and effectiveness of contraceptive use among women with CKD; all study designs were included. We extracted data from included articles; for studies that were not case series or case reports, we assessed risk of bias and determined certainty of evidence for each outcome.
Thromb Res
September 2025
Department of Hematology, Radboud university medical centre, Nijmegen, the Netherlands; Hemophilia Treatment Centre Nijmegen-Eindhoven-Maastricht, Nijmegen, the Netherlands. Electronic address:
Introduction: Very rare bleeding disorders (VRBDs) are hereditary disorders which cause increased risk of bleeding. In general, VRBDs consists of rare platelet function disorders, very rare coagulation factor deficiencies (other than Factor (F) VIII or FIX) and disorders of the fibrinolytic pathway. The rarity of these disorders along with the scarcity of specialized hemostasis laboratories capable to perform the necessary diagnostic tests, results in significant challenges in diagnosing and monitoring patients with VRBD.
View Article and Find Full Text PDFHum Reprod Update
September 2025
Women's Health Research Collaborative, New York, NY, USA.
Background: Reproductive-age women with intrauterine adhesions (IUAs) following uterine surgery may be asymptomatic or may experience light or absent menstruation, infertility, preterm delivery, and/or peripartum hemorrhage. Understanding procedure- and technique-specific risks and the available evidence on the impact of surgical adjuvants is essential to the design of future research.
Objective And Rationale: While many systematic reviews have been published, most deal with singular aspects of the problem.